RT Journal Article
SR Electronic
T1 Morphine for dyspnoea in chronic obstructive pulmonary disease: a before–after efficacy study
JF BMJ Supportive & Palliative Care
JO BMJ Support Palliat Care
FD British Medical Journal Publishing Group
SP 427
OP 432
DO 10.1136/bmjspcare-2019-001929
VO 11
IS 4
A1 Yoshinobu Matsuda
A1 Tatsuya Morita
A1 Hirotaka Matsumoto
A1 Keita Hosoi
A1 Kayo Kusama
A1 Yasuo Kohashi
A1 Hiroshi Morishita
A1 Sawako Kaku
A1 Keisuke Ariyoshi
A1 Shunsuke Oyamada
A1 Yoshikazu Inoue
A1 Satoru Iwase
A1 Takuhiro Yamaguchi
A1 Mitsunori Nishikawa
YR 2021
UL http://spcare.bmj.com/content/11/4/427.abstract
AB Objectives Dyspnoea in patients with chronic obstructive pulmonary disease (COPD) is frequent and often persists despite conventional treatment. This study aimed to evaluate the efficacy and safety of oral morphine for dyspnoea in Japanese COPD patients.Methods We conducted a multi-institutional, prospective, before–after study of morphine in COPD patients with dyspnoea at rest in seven hospitals. Patients received 12 mg of oral morphine per day (or 8 mg per day if low body weight or renal impairment). Primary outcome was change in the numerical rating scale (NRS) of current dyspnoea in the evening from Day 0 to Day 2. Secondary outcomes included changes in dyspnoea intensity in the evening from Day 0 to Day 1, dyspnoea intensity between the morning from Day 0 to Day 1 and Day 2, vital signs, nausea, somnolence, anorexia and other adverse events (AEs).Results A total of 35 patients were enrolled in this study between October 2014 and January 2018. One patient did not receive study treatment. Data from 34 patients was analysed. The NRS of dyspnoea intensity in the evening significantly decreased from 3.9 on Day 0 (95% CI: 3.1 to 4.8) to 2.4 on Day 2 (95% CI: 1.7 to 3.1; p=0.0002). Secondary outcomes significantly improved in a similar manner. There were no apparent changes in the mean scores of the opioid-related AEs and vital signs. One patient experienced grade 3 lung infection not associated with morphine. Other AEs were mild.Conclusion Oral morphine is effective in alleviating dyspnoea in Japanese COPD patients. Trial registration UMIN000015288 (http://www.umin.ac.jp/ctr/index.htm).No data are available.